Bradley Pharmaceuticals

Summary

Bradley Pharmaceuticals, Inc.
TypeMerged
IndustryPharmaceuticals
Founded1985; 36 years ago (1985)
Fateclosed February 21, 2008
SuccessorNycomed
HeadquartersFairfield Township, Essex County, New Jersey
Key people
Daniel Glassman (CEO)
ProductsAdoxa, Zoderm, Pamine Forte, Kerol
RevenueUS$145 million (2006)
Number of employees
300 (as of December 31, 2006)
Websitewww.bradpharm.com

Bradley Pharmaceuticals was a pharmaceutical company headquartered in Fairfield Township, Essex County, New Jersey.[1] The company was founded in 1985 by Daniel Glassman who was also its CEO.

The company marketed to niche physician specialties in the U.S. and 38 international markets. Bradley Pharmaceuticals comprised Doak Dermatologics, specialized in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.

Doak Dermatologics

Doak Dermatologics was the division of Bradley Pharmaceuticals that marketed products to dermatologists. Its flag products were Zoderm which is a topical anti-acne product. Adoxa (doxycycline) was an antibiotic intended to treat mild to severe acne.

Kenwood Therapeutics

Kenwood was the affiliate brand that worked with therapeutic products. Among the most prescribed ones were Entsol which is a respiratory therapeutic product and Pamine which is intended to treat digestive problems.

Public trading

The company was publicly traded at the NYSE by its code BDY since May 2003.

Nycomed Merger

Bradley Pharmaceuticals merged with Nycomed, a European company. The merger was completed on February 21, 2008, and Bradley became an integral part of Nycomed.[2]

References

  1. ^ "Company Overview of Bradley Pharmaceuticals, Inc". Bloomberg Businessweek. September 17, 2014.
  2. ^ "Fougera which acquired Nycomed)". Archived from the original (PDF) on 11 February 2012. Alt URL